La catena delle opzioni mostra i dati chiave delle opzioni azionarie di MAIA Biotechnology a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per MAIA Biotechnology..

MAIA Biotechnology (AMEX:MAIA) Azioni, Catena delle Opzioni

MAIA Biotechnology

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

MAIA Biotechnology Inc

SI-BONE, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>), a&nbsp;Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced that the Centers for Medicare &amp; Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for the iFuse Bedrock Granite&#x2122; (Granite) system, used for pelvic fixation and sacroiliac joint fusion in conjunction with lumbar spinal fusion procedures, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment status, which will be effective up to three years beginning January 1, 2025, allows patient access to new and innovative technology like Granite by providing an add-on payment to hospitals and ambulatory surgery centers supporting it.
As part of the TPT determination, CMS confirmed that a customary deduction from the add-on payment, known as a device offset, will not be applied to lumbar spinal fusion procedures involving pelvic fixation with Granite. This decision recognizes that Granite costs are not currently included in the existing facility payment amount for the procedures using this technology.

Biotech

News

General

SIBN

SI-BONE Receives Transitional Pass-Through Payment Status For iFuse Bedrock Granite System, Used For Pelvic Fixation And Sacroiliac Joint Fusion In Conjunction With Lumbar Spinal Fusion Procedures, Under The Medicare Hospital Outpatient Prospective Payment System

SPPL

Simpple Ltd, A Leading Technology Provider Announced Its Plan To Regain NASDAQ Compliance

Guidance

BLDP

Ballard Power Systems Expects Revenue In 2024 To Be Weighted Towards Q4

The New York State Common Retirement Fund has significantly reduced its stake in Vistra Corp., according to a recent filing with the Securities &amp; Exchange Commission (SEC). This move was executed during the third quarter.
What Happened: The fund divested 43,440 shares, marking a 21.6% reduction in its Vistra Corp. holdings. Following this transaction, the fund retains 157,565 shares of the company&#8217;s stock, valued at $18,678,000 as per the latest SEC filing. This adjustment is part of the fund&#8217;s broader portfolio management strategy.
The change in the portfolio comes at a time when Vistra Corp&#8217;s year-to-date (YTD) returns have crossed 200%. As per Benzinga Pro, Vistra Corp was trading 0.24% higher on Tuesday during pre-market than its previous day close at $115.74.
See Also: <a href="https://www.benzinga.com/news/24/11/41705158/cathie-wood-says-trumps-ideas-on-eliminating-income-tax-and-imposing-tariffs-brings-back-vibes-of-ea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood Says Trump&#8217;s Ideas On Eliminating Income Tax And Imposing Tariffs Brings Back Vibes Of &#8216;Early</a>
Why It Matters: Texas-based Vistra Corp. <a href="https://www.benzinga.com/insights/news/24/11/41715992/evaluating-vistra-against-peers-in-independent-power-and-renewable-electricity-producers-industry">stands as a major player</a> in the Independent Power and Renewable Electricity Producers industry. It is one of the largest power producers and retail energy providers in the U.S., especially after acquiring Energy Harbor in 2024. This acquisition expanded Vistra&#8217;s portfolio to include 41 gigawatts of nuclear, coal, natural gas, and solar power generation, alongside one of the world&#8217;s largest utility-scale battery projects.
Vistra&#8217;s retail electricity business serves approximately 5 million customers across 20 states, covering nearly a third of Texas&#8217;s electricity consumers. The company emerged as an independent entity in 2016 after the bankruptcy of Energy Future Holdings and further expanded by acquiring Dynegy in 2018.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41705665/palantir-technologies-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Palantir Technologies Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Top Analysts</a></li>
</ul>
Image via Midjourney
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Equities

Markets

New York State Common Retirement Fund Pares Vistra Corp Stake After Shares Rally Over 200% This Year

Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that ART26.12, the Company's lead clinical FABP inhibitor, has been accepted into the NIH Helping to End Addiction Long Term (HEAL) Initiative's Preclinical Screening Platform for Pain (PSPP).
The HEAL Initiative is an NIH-wide effort to accelerate scientific solutions to the overdose epidemic, including opioid and stimulant use disorders, and the crisis of pain. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. For more information, visit: <a href="https://www.globenewswire.com/Tracker?data=V0OIqyLfFcY5W7pjPpAuOgSxpFF0XIvawVscW4wbdwg7V_FhA3Ltt3AEUAniLYFzGCWmQxbGtaOlCTeoy9z_gw==">https://heal.nih.gov</a>.
The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical pain models. The PSPP program accepts small molecules, biologics,&nbsp;devices,&nbsp;or natural products for evaluation, from researchers in academia and industry worldwide. For more information, visit: <a href="https://www.globenewswire.com/Tracker?data=V0OIqyLfFcY5W7pjPpAuOlGjlyIIOqxGCXGg7oAt6Z8k_ceVEneHLI1vwxQ_6cUhkiltyTw8QQT1pV5d70643HL2HPZdhRFfxJaV9YNhfRmH9nfw_RF6CKHtAfA4IrI-OAUc2GDix2f8AgJTeD-gGsZnWraYf9DQLl_KK0KyPERmmZ2qiTanbmibjkbPuCBhaatGJ8TqR2NK9mw7c9BFBPeEx1kzbGwZK3J_7R1YWB0=">https://heal.nih.gov/research/preclinical-translational/screening-platform</a>.
The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

ARTL

Artelo Biosciences Announces Acceptance Of ART26.12 Into The National Institutes Of Health's Helping To End Addiction Long Term Initiative's Preclinical Screening Platform For Pain

WIIM

MPLX

MPLX shares are trading higher. The company reported Q3 financial results.

TCMD

Tactile Systems Tech shares are trading lower after BTIG downgraded the stock from Buy to Neutral.

Ballard Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.13) by 423.08 percent. The company reported quarterly sales of $14.800 million which missed the analyst consensus estimate of $23.556 million by 37.17 percent. This is a 46.33 percent decrease over sales of $27.575 million the same period last year.

Earnings

Earnings Misses

Ballard Power Systems Q3 2024 GAAP EPS $(0.68) Misses $(0.13) Estimate, Sales $14.800M Miss $23.556M Estimate

UL Solutions shares are trading higher after the company reported better-than-expect Q3 financial results.

<a href="https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss" title="https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss">https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss</a>

BEAM

Patient In Beam Therapeutics' CRISPR Trial For Sickle Cell Disease Dies From Likely Chemotherapy Complications; Early Signs Of Gene Editing Effectiveness Observed In Other Participants

Management

PHUN

Phunware Names Rahul Mewawalla As Chairman Of The Board To Lead Growth And Innovation In AI, Predictive Analytics, And Cloud Services

Vaccinex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD) through the inhibition of SEMA4D, today announced that it will present new biomarker data that neoadjuvant treatment with pepinemab enhanced the clinical activity of immune checkpoint inhibitors in poorly immunogenic, HPV-negative, head and neck cancer (HNSCC). In a presentation at Society for Immunotherapy of Cancer's Annual Meeting (SITC) on November 8th, Vaccinex will present data from the Phase 2 KEYNOTE-B84 study (NCT04815720) for treatment of recurrent and metastatic disease as well as an independent study evaluating neoadjuvant treatment of resectable HNSCC (NCT03690986) showing that pepinemab combination treatments appear to induce mature lymphoid aggregates correlating with clinical benefit within immunotherapy resistant tumor populations, including HPV-negative and PD-L1 low HNSCC.

VCNX

Vaccinex Reports Improved Immunity Correlating With Clinical Benefit Of Pepinemab Combination Treatment At Society For Immunotherapy Of Cancer's Annual Meeting

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) with a Buy and raises the price target from $36 to $42.

Price Target

Analyst Ratings

VRNA

HC Wainwright & Co. Maintains Buy on Verona Pharma, Raises Price Target to $42

JP Morgan analyst Matthew Boss maintains Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Neutral and lowers the price target from $97 to $82.

JP Morgan Maintains Neutral on Dollar Gen, Lowers Price Target to $82

Expeditors Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NASDAQ">EXPD</a>) reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1.35 by 20.74 percent. The company reported quarterly sales of $3.000 billion which beat the analyst consensus estimate of $2.444 billion by 22.76 percent. This is a 36.99 percent increase over sales of $2.190 billion the same period last year.

Earnings Beats

EXPD

Expeditors Intl Q3 2024 GAAP EPS $1.63 Beats $1.35 Estimate, Sales $3.000B Beat $2.444B Estimate

CSLR

Complete Solar Sees Prelim. Q3 Revenue $117.3M

Macro Economic Events

Econ #s

Economics

USA Exports 267.95B; 271.80B Prior

Plug Power Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) has big dreams for a <a href="https://www.benzinga.com/topic/hydrogen">green hydrogen-powered future</a>, but it might hit some potholes before reaching that destination. 
JPMorgan's Bill Peterson brings a cautiously balanced view, signaling that while Plug Power's ambitions shine bright, the near-term realities could dampen the sparkle for investors. As we speed toward the company's third-quarter earnings call on Nov. 12 and its annual Plug Symposium on Nov. 13, expectations are mixed, with both high hopes and real risks.
<h2 class="wp-block-heading">Watch For Roadblocks Heading Into H2</h2>
Plug Power has set its sights high, predicting substantial growth in its hydrogen-driven Energy business and aiming to double revenue in the second half of 2024. 
However, hitting these targets will require a serious acceleration in sales—especially in the softer material handling sector and a reliable revenue boost in electrolyzer equipment. But with a sluggish U.S. hydrogen market and the 45V tax credit still a question mark, this quarter's results may land below expectations, with Plug likely to fall short of the high double-digit growth needed to meet the lower end of its guidance range, the analyst said.
Read Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41713236/donald-trumps-return-to-white-house-could-propel-these-etfs-to-new-highs" target="_blank" rel="noreferrer noopener">Donald Trump's Return To White House Could Propel These ETFs To New Highs</a>
<h2 class="wp-block-heading">The Symposium Spotlight: A Blueprint For Long-Term Growth</h2>
At the upcoming Plug Symposium, management is expected to emphasize its roadmap beyond quarterly earnings.
Plug Power could unveil its vision for reaching $20 billion in revenue by 2030, a bold ambition that Peterson considers likely to face practical constraints. While the Symposium may inspire with case studies in hydrogen applications and potential growth in mobility and stationary power, Plug will need to prove its green hydrogen network can yield real profits, especially as global interest in hydrogen faces increasing skepticism around commercial viability.
<h2 class="wp-block-heading">Short-Term Jitters With A Dash Of Optimism</h2>
Plug Power's short-term outlook carries a dose of volatility, partly fueled by ongoing political uncertainty. The company may reiterate its guidance, but Peterson remains unconvinced it's achievable, seeing risks in the 2024 market landscape.
Although PLUG stock's 28% short interest reflects broad market wariness, a clear policy signal or an unexpected DOE loan closure could still spark some interest. For now, though, Plug is under pressure to execute margin improvements and make tangible progress on cash flow management before it can comfortably court long-term investors.
<h2 class="wp-block-heading">Staying Neutral, But Watching The Horizon</h2>
JPMorgan's Peterson is staying neutral on PLUG, balancing near-term headwinds with the potential long-term upside if hydrogen gains a foothold. 
While Plug Power's green hydrogen goals are audacious, the company faces cash flow and demand challenges that can't be overlooked. 
For investors, the message is clear: stay buckled up for a bumpy ride, and don't lose sight of the possible rewards if Plug Power can overcome its hurdles and secure a sustainable path forward in the green hydrogen revolution.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/esg/24/11/41722922/trump-vs-harris-evgo-cleveland-cliffs-plug-power-nucor-brace-for-2024-election-impact">Trump Vs. Harris: EVgo, Cleveland-Cliffs, Plug Power, Nucor Brace For 2024 Election Impact</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Trading Ideas

PLUG

Plug Power's $20 Billion Revenue Ambition Faces Obstacles, Analyst Says

Colony Bankcorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAN#NASDAQ">CBAN</a>) ("Colony" or the "Company") the parent company of Colony Bank, announced today that it is transferring the listing of its common stock to the New York Stock Exchange (NYSE) from The Nasdaq Stock Market LLC (Nasdaq).
Colony Bankcorp's common stock is expected to begin trading on the NYSE on November 18, 2024, under the ticker symbol of "CBAN." Colony Bankcorp expects its common stock to continue to trade on Nasdaq until the close of the market on November 15, 2024.

CBAN

Colony Bankcorp Announces Transfer Of Listing Of Common Stock To The NYSE From The Nasdaq Stock Market; Expected To Begin Trading On The NYSE On November 18, 2024

JP Morgan analyst Matthew Boss maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Neutral and raises the price target from $70 to $82.

DLTR

JP Morgan Maintains Neutral on Dollar Tree, Raises Price Target to $82

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MAIA Biotechnology (NYSEMKT:<a href="https://investorplace.com/stock-quotes/maia-stock-quote/">MAIA</a>) just reported results for the first quarter of 2024.<ul><li>MAIA Biotechnology reported earnings per share of -46 cents. This was below the analyst estimate for EPS of -39 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/maia-stock-earnings-maia-biotechnology-for-q1-of-2024/">MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024

ASTS, ALLO and CMCM are among premarket gainers

MAIA Biotechnology, Inc. (MAIA) has shared an update. MAIA Biotechnology, Inc. has announced promising results from its Phase 2 THIO-101 clinical t...

MAIA Biotechnology Unveils Promising THIO-101 Trial Results

Recent Run-Up Provides MAIA Biotechnology With Breathing Room

MAIA Biotechnology, Inc. (MAIA) has issued an announcement. MAIA Biotechnology, Inc. recently updated investors with a presentation and summary on ...

MAIA Biotechnology Highlights Clinical Progress and Investor Insights

An announcement from MAIA Biotechnology, Inc. (MAIA) is now available. MAIA Biotechnology, Inc. has announced significant year-to-date achievements...

MAIA Biotechnology Reports Progress in Cancer Drug Development

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MAIA Biotechnology (NYSEMKT:<a href="https://investorplace.com/stock-quotes/maia-stock-quote/">MAIA</a>) just reported results for the second quarter of 2024.<ul><li>MAIA Biotechnology reported earnings per share of -40 cents. This was below the analyst estimate for EPS of -39 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/maia-stock-earnings-maia-biotechnology-for-q2-of-2024/">MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q2 2024

MAIA Biotechnology, Inc. ( ($MAIA) ) has shared an announcement. MAIA Biotechnology, Inc. is actively engaging with the financial community, presen...

MAIA Biotechnology Advances with Clinical Trials and Partnerships

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report), with ...

Noble Financial Reaffirms Their Buy Rating on MAIA Biotechnology, Inc. (MAIA)

MAIA Biotechnology prices $2.44M private placement

AGBA

ALLO

ASTS

BCAN

CMCM

EDBL

MAIA

MNDR

SILO

Screenshot 2024-09-10 at 8.49.39 PM

REGN

MAIA Biotechnology&#39;s Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Screenshot 2024-06-06 at 5.43.20 PM

New Clinical Data Reveals MAIA Biotechnology&#39;s THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment

Screenshot 2024-05-21 at 5.35.44 PM

MAIA Biotechnology&#39;s Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market

Screenshot 2024-02-28 at 6.41.05 PM

MAIA Biotech Completes Enrollment For Phase 2 Trial Of Its Candidate THIO To Fight Non-Small Cell Lung Cancer

Press Releases

MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO

New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment

MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy

FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer

MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics

MAIA Biotechnology Announces $2.44 Million Private Placement

ADMA

BMRN

CORT

EXEL

GMAB

HALO

INCY

JAZZ

MDXG

TECH

UTHR

VRTX

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Coherus BioSciences

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

CytomX Therapeutics

Citius Oncology

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

IO Biotech

Kronos Bio

Metagenomi

Monopar Therapeutics

Mural Oncology

Omega Therapeutics

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

RAPT Therapeutics

Serina Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Spero Therapeutics

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

Xilio Therapeutics

Noble Capital Markets

Comments

MAIA Biotechnology

MAIA Biotechnology (MAIA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO